Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT01336140
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 300 participants
- Registry
-
NCT01336140
-
- Other papers using this trial's data
- Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01336140. Randomized; quadruple masking; primary purpose prevention. Start 2011-06 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-02-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
- Acronym
- ASSUAGE-CKD
- Condition
- Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
- Intervention (Drug)
- Aminophylline
- Intervention (Drug)
- Placebo
- Lead sponsor
- Rush University Medical Center
- Collaborator
- Cook County Health
Record details
- Record id
cardio:ct-nct01336140- Content hash
cdb2f72ff663eada39c1188a715a5309d8400a21b04b089daa7b3b26d9720fee